CSPC Re-selected into TOP 25 Global Pharmaceutical Companies by Pipeline Size

Recently, Citeline, a world-renowned provider of drugs, medical devices, pharmaceutical companies, clinical trials, and a market intelligence, released the Pharma R&D Annual Review 2024 (all data were collected as of January 2, 2024). Citeline provided Top 25 pharmaceutical companies by pipeline size in this report. CSPC was included on the list for the second consecutive year, taking the 24th position.

The report shows that the global R&D pipeline size in 2023 has again hit a new high, with the expansion rate on the up again. For the first time, CSPC was selected into the Top 25 global pharmaceutical companies by pipeline size in 2023, and the year 2024 saw the second selection of CSPC. CSPC has always believed that innovative R&D is the most important engine driving the Group's future development, so the Group continues to increase investment in R&D pipeline development. In 2023, CSPC's R&D investment reached RMB 4.83 billion (included in the income statement), representing a year-on-year increase of 21.2%, accounting for 18.8% of the income from the patent medicine business.

Currently, CSPC has more than 60 key drugs under development that have been in the stages of clinical trial or application, 7 of which have been subject to the submission of a marketing authorization application and 18 are in the registered clinical stage.

As of January 2, 2024, a total of 22,825 drugs are under development worldwide, representing a year-on-year increase of 7.20%, exceeding the average growth rate (7.14%) of the past five years.

Chinese pharmaceutical companies are increasingly becoming the backbone of the pharmaceutical world map. Statistics show that companies headquartered in China increased by 3%. In terms of R&D activities, the proportion of drug R&D activities involving China rose by 3.1% to 26.7%, making China the world's second-largest drug developer, behind only the United States.

Looking forward, CSPC will stay committed to developing self-developed pipelines via our eight existing innovative technology platforms, adhere to the orientation of satisfying clinical needs, and make efforts to find new targets and explore gene therapy, cell therapy and other emerging fields so as to make our contributions to further integrate Chinese pharmaceutical companies into the international map.